Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call
Spectral AI (NASDAQ: MDAI), developer of the AI-driven DeepView® System for burn healing prediction, has scheduled its fourth quarter and full year 2024 financial results announcement for March 27, 2025, after market close.
The company will host a conference call at 5:00 pm Eastern Time to discuss the results. Investors can participate by dialing 844-481-3008 (U.S.) or 412-317-1892 (International). A simultaneous webcast will be available through the Events & Presentations section of Spectral AI's Investor Relations website.
The DeepView® System, which received FDA Breakthrough Device Designation in 2018, utilizes multi-spectral imaging and AI algorithms to predict burn healing potential.
Spectral AI (NASDAQ: MDAI), sviluppatore del sistema DeepView® basato su intelligenza artificiale per la previsione della guarigione delle ustioni, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 27 marzo 2025, dopo la chiusura del mercato.
L'azienda ospiterà una teleconferenza alle 17:00 ora orientale per discutere i risultati. Gli investitori possono partecipare componendo il numero 844-481-3008 (U.S.) o 412-317-1892 (Internazionale). Sarà disponibile una trasmissione in diretta simultanea attraverso la sezione Eventi e Presentazioni del sito web delle Relazioni con gli Investitori di Spectral AI.
Il sistema DeepView®, che ha ricevuto la Designazione di Dispositivo Innovativo dalla FDA nel 2018, utilizza l'imaging multispettrale e algoritmi di intelligenza artificiale per prevedere il potenziale di guarigione delle ustioni.
Spectral AI (NASDAQ: MDAI), desarrollador del sistema DeepView® impulsado por IA para la predicción de la curación de quemaduras, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 27 de marzo de 2025, después del cierre del mercado.
La compañía llevará a cabo una conferencia telefónica a las 5:00 pm hora del Este para discutir los resultados. Los inversores pueden participar llamando al 844-481-3008 (EE. UU.) o al 412-317-1892 (Internacional). Una transmisión web simultánea estará disponible a través de la sección de Eventos y Presentaciones en el sitio web de Relaciones con Inversores de Spectral AI.
El sistema DeepView®, que recibió la Designación de Dispositivo Innovador de la FDA en 2018, utiliza imágenes multiespectrales y algoritmos de IA para predecir el potencial de curación de las quemaduras.
스펙트럴 AI (NASDAQ: MDAI)는 화상 치유 예측을 위한 AI 기반 DeepView® 시스템의 개발업체로, 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 27일 시장 종료 후로 예정했습니다.
회사는 결과를 논의하기 위해 동부 표준시 오후 5시에 전화 회의를 개최합니다. 투자자들은 844-481-3008 (미국) 또는 412-317-1892 (국제)로 전화하여 참여할 수 있습니다. Spectral AI의 투자자 관계 웹사이트의 이벤트 및 발표 섹션을 통해 동시에 웹캐스트가 제공됩니다.
DeepView® 시스템은 2018년에 FDA의 혁신 기기 지정을 받은 장치로, 다중 스펙트럼 이미징과 AI 알고리즘을 사용하여 화상 치유 가능성을 예측합니다.
Spectral AI (NASDAQ: MDAI), développeur du système DeepView® alimenté par IA pour la prédiction de la guérison des brûlures, a prévu l'annonce de ses résultats financiers pour le quatrième trimestre et l'année complète 2024 pour le 27 mars 2025, après la fermeture du marché.
La société organisera une conférence téléphonique à 17h00 heure de l'Est pour discuter des résultats. Les investisseurs peuvent participer en composant le 844-481-3008 (États-Unis) ou le 412-317-1892 (International). Un webinaire simultané sera disponible dans la section Événements et Présentations du site web des Relations Investisseurs de Spectral AI.
Le système DeepView®, qui a reçu la désignation de Dispositif Innovant de la FDA en 2018, utilise l'imagerie multispectrale et des algorithmes d'IA pour prédire le potentiel de guérison des brûlures.
Spectral AI (NASDAQ: MDAI), Entwickler des KI-gesteuerten DeepView®-Systems zur Vorhersage der Heilung von Verbrennungen, hat die Bekanntgabe seiner Finanzzahlen für das vierte Quartal und das Gesamtjahr 2024 auf den 27. März 2025 nach Börsenschluss festgelegt.
Das Unternehmen wird um 17:00 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu diskutieren. Investoren können teilnehmen, indem sie 844-481-3008 (USA) oder 412-317-1892 (International) anrufen. Eine gleichzeitige Webcast wird im Bereich Veranstaltungen & Präsentationen der Investor Relations-Website von Spectral AI verfügbar sein.
Das DeepView®-System, das 2018 die FDA Breakthrough Device Designation erhielt, nutzt multispektrale Bildgebung und KI-Algorithmen, um das Heilungspotenzial von Verbrennungen vorherzusagen.
- FDA Breakthrough Device Designation status for DeepView System
- None.
DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 27, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.
Investors interested in participating in the live call can dial:
- 844-481-3008 - U.S.
- 412-317-1892 - International
A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.
Forward Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,”
“may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward- looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward- looking statements.
For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free – U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com
FAQ
When will Spectral AI (MDAI) release its Q4 and full year 2024 earnings?
How can investors join Spectral AI's (MDAI) Q4 2024 earnings call?
What is Spectral AI's (MDAI) DeepView System used for?
When did Spectral AI's (MDAI) DeepView System receive FDA Breakthrough Device Designation?
